United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) shared today it has broadened its portfolio of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) following a favorable vote for ABRYSVO™ [Respiratory Syncytial Virus Vaccine], the company's bivalent RSV prefusion F (RSVpreF) vaccine, as a maternal immunization. This is the first-ever fall in which eligible individuals can receive Pfizer vaccines to.

Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV

A Centers for Disease Control and Prevention advisory committee on Friday recommended pregnant people get Pfizer Inc.'s PFE, -0.56% maternal vaccine to protect babies from respiratory syncytial virus. RSV affects the lungs and breathing passages and is a leading cause of hospitalization among U.S. babies.

Pfizer maternal RSV vaccine recommended by CDC advisors

CDC Director Mandy Cohen still needs to sign off on that recommendation before mothers can receive Pfizer's shot to protect their infants from RSV.

CDC advisors recommend Pfizer maternal RSV vaccine to protect infants

GlaxoSmithKline

Advisers to the U.S. Centers for Disease Control and Prevention (CDC) are meeting on Friday to discuss recommendations for use of the first vaccine for respiratory syncytial virus (RSV) approved for pregnant women to protect their babies.

Explainer: What you need to know about RSV and the new vaccines

A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Friday will vote on the use of Pfizer's respiratory syncytial virus (RSV) vaccine in pregnant women, likely paving the way for it to become the country's first maternal shot for protecting babies from the virus.

US CDC panel weighs use of Pfizer's maternal RSV vaccine to protect infants

Amgen

Amgen's prospects remain solid despite recent struggles. Pfizer is poised to show that it isn't just a pandemic stock.

2 Dividend Growth Stocks to Buy Right Now

Ares Commercial Real Estate

BrightSpire Capital

British American Tobacco

Cornerstone Strategic Value Fund Inc

Cornerstone Total Return Fund Inc

FS Credit Opportunities Corp

FS KKR Capital Corp

AG Mortgage Investment Trust

Realty Income Corp

Oxford Lane Capital

Petroleo Brasileiro

AT&T

Vodafone Group

Walgreens

Prior to August 31, 2023, my Readers mentioned 37 equities in their comments on my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, these are ReFa/Ro. Ten analyst-target-estimated TOP-NET-GAIN Re/Fa/Ro: PFE, PBR, O, T, BRSP, BTI, PRB.A, VOD, WBA, and MITT, averaged 48.7% net gains from reader data collected 8/18/23. Ten analyst-target-augured August TOP-PRICE-UPSIDE reader faves & rogues (ReFa/Ro) were: MMM, KHC, BRSP, T, O, PFE, BTI, VOD, WBA, & MITT boasting a 46.54% average target price upside estimate.

Readers Post 32 August Dividend Buy Candidates

BioNTech SE

Moderna

Facing significant patent cliffs, Pfizer is putting faith in new launches. Moderna has nearly doubled its pipeline in three years.

With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?

AbbVie

CRISPR Therapeutics

Johnson & Johnson

Eli Lilly

Molina Healthcare

Merck

Novo Nordisk

Seagen

UnitedHealth Group

If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.

Flee to Healthcare Stocks if Recession Rears its Head?

AstraZeneca

AstraZeneca PLC (LSE:AZN) shares rose 2.4% to 10,868p after its Alexion rare disease unit sealed a deal to buy a portfolio of Pfizer's early-stage drugs to boost its footprint in the burgeoning field of genomic medicine for up to US$1bn. As well as buying and licencing the rare disease gene therapy assets, Alexion has agreed to pay royalties based on levels of potential future sales.

AstraZeneca rises on completion of Pfizer gene therapy deal

Pfizer (PFE) gets marketing authorization in the EU for Litfulo to treat adults and adolescent patients aged 12 years and older with severe alopecia areata.

Pfizer's (PFE) Alopecia Areata Drug Litfulo Receives EU Nod

Pfizer is planning to acquire businesses and assets to power its growth. It'll be fighting against falling coronavirus medicine sales and also generic drugs.

Pfizer Stock: Bear vs. Bull

Citigroup

Chevron

Target

TotalEnergies SE

Unilever

Looking for dividend stocks yielding 3% or more might seem pretty specific. Remember, though, the logic behind investing in underrated stocks is straightforward: Buy low and sell high in order to see a healthy return on your investment.

The Top 7 Underrated Dividend Stocks Yielding 3% or More

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for LITFULO™ (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe alopecia areata. LITFULO, a once-daily oral capsule, is the first medicine authorized by the EC to treat individuals as young as 12 years of age with severe alopecia areata. LITFULO is also the first and only treatment to selectively inhibit Janus kinase 3 (JAK3).

European Commission Approves Pfizer's LITFULO™ for Adolescents and Adults With Severe Alopecia Areata

Moderna (MRNA) was the worst-performing stock in the S&P 500 as shares dropped 9% after Pfizer CFO David Denton said the outlook for vaccine rates this year got a significant "haircut." Pfizer (PFE) shares also dropped, declining 1%.

Shares of COVID-19 Vaccine Makers Fall After Pfizer CFO Warns of Outlook 'Haircut'

Pfizer Inc. (NYSE:PFE ) J.P. Morgan 14th Annual U.S. All Stars Conference September 18, 2023 12:15 PM ET Company Participants Ronen Tamir - IR David Denton - CFO Conference Call Participants Christopher Schott - Morgan Stanley Christopher Schott We're ready to go.

Pfizer Inc. (PFE) J.P. Morgan 14th Annual U.S. All Stars Conference (Transcript)

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 31, 2023. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Third Quarter 2023 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Info.

Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts

Pfizer expects 24% vaccination rate in the United States for this fall with its COVID vaccines, chief financial officer David Denton said at a conference on Monday.

Pfizer expects 24% uptake of COVID vaccines in US - CFO

Pfizer's $43 billion bid for Seagen will be decided by EU antitrust regulators by Oct. 19, a regulatory filing showed on Friday.

EU antitrust regulators set Oct. 19 deadline for Pfizer's Seagen deal

Bristol-Myers

It's been a rough year to invest in pharma stocks. The industry is adjusting to a sector that is less reliant on Covid-19 vaccines and is adapting to the effects of inflation as well as pressure from regulators to cap the price of many drugs.

The 3 Most Undervalued Pharma Stocks to Buy in September 2023

Sanofi

Pfizer and Sanofi both earned approval for RSV vaccines this year. This market alone won't be a major growth driver for these companies.

This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now

News for Pfizer Stock (PFE)